Steven Cohen’s Cullinan Therapeutics CGEM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-75,009
Closed -$1.37M – 4003
2026
Q2
$1.37M Sell
75,009
-830,367
-92% -$12.3M ﹤0.01% 2630
2026
Q1
$12.9M Buy
905,376
+545,214
+151% +$7.01M 0.02% 1070
2025
Q4
$3.73M Buy
+360,162
New +$3.25M ﹤0.01% 2049
2023
Q4
– Sell
-224
Closed -$2.03K – 2236
2023
Q3
$2.03K Sell
224
-1,801
-89% -$18.8K ﹤0.01% 2364
2023
Q2
$21.8K Buy
+2,025
New +$21.5K ﹤0.01% 1767

Other funds holding CGEM

Steven Cohen's CGEM Position: Q3 2026 in Review

Steven Cohen sold out of Cullinan Therapeutics (CGEM) in Q3 2026, closing a stake of 75,009 shares — an estimated $1.37M sold.

Steven Cohen first reported a position in CGEM in Q2 2023 and held it in 5 quarters. The position peaked at $12.9M in Q1 2026. 182 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.

  • Steven Cohen reported no remaining Cullinan Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Steven Cohen sold 75,009 Cullinan Therapeutics shares in Q3 2026, an estimated $1.37M.
  • Steven Cohen first reported a position in Cullinan Therapeutics in Q2 2023 and held it in 5 quarters.
  • Steven Cohen's Cullinan Therapeutics position peaked at $12.9M in Q1 2026.
  • 182 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.